Savior LLC recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
800 SOUTH STREET WALTHAM, MA 02453
As of the latest 13F report, the guru’s equity portfolio contained 177 stocks valued at a total of $112.00Mil. The top holdings were SYLD(9.63%), SPHQ(9.21%), and FNY(8.43%).
According to GuruFocus data, these were Savior LLC’s top five trades of the quarter.
First Trust Materials AlphaDEX Fund
Savior LLC reduced their investment in ARCA:FXZ by 121,606 shares. The trade had a 6.31% impact on the equity portfolio. During the quarter, the stock traded for an average price of $58.61.
On 01/13/2023, First Trust Materials AlphaDEX Fund traded for a price of $68.14 per share and a market cap of $1.59Bil. The stock has returned 8.45% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, First Trust Materials AlphaDEX Fund has a price-earnings ratio of 6.50 and a price-book ratio of 1.83.
ProShares Ultra Silver 2x Shares
The guru established a new position worth 182,638 shares in ARCA:AGQ, giving the stock a 3.53% weight in the equity portfolio. Shares traded for an average price of $21.62 during the quarter.
On 01/13/2023, ProShares Ultra Silver 2x Shares traded for a price of $32.74 per share and a market cap of $420.60Mil. The stock has returned -3.68% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
SPDR Biotech ETF
The guru established a new position worth 45,182 shares in ARCA:XBI, giving the stock a 3.34% weight in the equity portfolio. Shares traded for an average price of $84.31 during the quarter.
On 01/13/2023, SPDR Biotech ETF traded for a price of $87.88 per share and a market cap of $8.80Bil. The stock has returned -10.42% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, SPDR Biotech ETF has a price-book ratio of 3.36.
ProShares Ultra S&P500 2x Shares
Savior LLC reduced their investment in ARCA:SSO by 73,015 shares. The trade had a 3.01% impact on the equity portfolio. During the quarter, the stock traded for an average price of $49.47.
On 01/13/2023, ProShares Ultra S&P500 2x Shares traded for a price of $48.13 per share and a market cap of $2.77Bil. The stock has returned -30.88% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
ProShares Ultra QQQ 2x Shares
Savior LLC reduced their investment in ARCA:QLD by 54,531 shares. The trade had a 2.08% impact on the equity portfolio. During the quarter, the stock traded for an average price of $47.53.
On 01/13/2023, ProShares Ultra QQQ 2x Shares traded for a price of $38.81 per share and a market cap of $2.66Bil. The stock has returned -51.39% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, ProShares Ultra QQQ 2x Shares has a price-earnings ratio of 25.32 and a price-book ratio of 6.70.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
